Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
results tags : Phase 3 save search
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Regeneron Pharmaceuticals, Inc. and Sanofi announced that a Phase 3 trial asses...
Published: 2022-07-14 (Crawled : 07:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results sanofi phase 3
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
Published: 2022-07-14 (Crawled : 06:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results phase 3
Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (SB206) in Patients with Molluscum Contagiosum in JAMA Dermatology
Published: 2022-07-13 (Crawled : 16:00) - prnewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: -2.0%
H: 22.45%
C: 4.08%
sb206 molluscum positive results publication study phase 3
Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
Published: 2022-07-06 (Crawled : 12:00) - globenewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 1.85%
H: 1.45%
C: 0.66%
VERU | $1.27 0.0% 2.6M
|
Health Technology
|
| O: 0.26%
H: 20.43%
C: 12.73%
covid-19 treatment sabizabulin trial results publication phase 3
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
Published: 2022-06-30 (Crawled : 01:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.51%
H: 0.0%
C: 0.0%
takhzyro children trial positive results phase 3
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
Published: 2022-06-28 (Crawled : 12:00) - biospace.com/
JAZZ | $109.685 0.79% 0.78% 380K
|
Health Technology
|
| O: -0.78%
H: 1.49%
C: -0.15%
trial results sclerosis phase 3 topline
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
Published: 2022-06-28 (Crawled : 12:00) - prnewswire.com
JAZZ | $109.685 0.79% 0.78% 380K
|
Health Technology
|
| O: -0.78%
H: 1.49%
C: -0.15%
trial results sclerosis phase 3 topline
Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
Published: 2022-06-13 (Crawled : 12:20) - biospace.com/
OPTN | $0.9709 -5.74% -6.09% 670K
|
Health Services
|
| O: 17.49%
H: 31.63%
C: 21.4%
treatment trial positive topline phase 3
Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia
Published: 2022-06-08 (Crawled : 12:20) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 3.02%
H: 0.98%
C: 0.34%
RIGL | $1.135 0.44% 0.44% 520K
|
Health Technology
|
| O: -45.22%
H: 9.28%
C: -21.07%
anemia trial results topline phase 3
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease
Published: 2022-06-07 (Crawled : 21:00) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450K
|
Health Technology
|
| O: -1.25%
H: 0.0%
C: 0.0%
conference disease eye trial therapeutics results topline phase 3
DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers
Published: 2022-06-07 (Crawled : 21:00) - globenewswire.com
DBVT | $0.6884 4.15% 3.98% 120K
|
Health Technology
|
| O: 19.61%
H: 0.0%
C: 0.0%
topline trial positive results phase 3
Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis
Published: 2022-06-06 (Crawled : 12:20) - biospace.com/
ARQT | $8.735 -2.29% -2.35% 1.6M
|
Health Technology
|
| O: 4.65%
H: 1.24%
C: -4.42%
topline dermatitis trial positive results phase 3
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
Published: 2022-06-04 (Crawled : 16:20) - prnewswire.com
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
| Email alert
Add to watchlist
cs-02 trodelvy sciences positive results cancer breast cancer phase 3 her2- her2 metastatic breast cancer
Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
Published: 2022-06-03 (Crawled : 14:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -2.68%
H: 0.0%
C: 0.0%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.37%
H: 0.0%
C: 0.0%
imbruvica risk disease results order phase 3
Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
Published: 2022-06-03 (Crawled : 11:00) - biospace.com/
IONS | $41.85 1.9% 1.86% 630K
|
Health Technology
|
| O: 0.11%
H: 2.24%
C: 1.03%
results phase 3
AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022
Published: 2022-06-01 (Crawled : 15:00) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.55%
H: 0.0%
C: 0.0%
rinvoq trials positive results phase 3
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease
Published: 2022-05-27 (Crawled : 08:00) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -1.98%
H: 0.0%
C: 0.0%
skyrizi disease lancet risankizumab results phase 3
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis
Published: 2022-05-27 (Crawled : 08:00) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -1.98%
H: 0.0%
C: 0.0%
rinvoq lancet results phase 3 ulcerative colitis
SIGMA LITHIUM ANNOUNCES FILING TECHNICAL REPORT WITH OUTSTANDING ECONOMIC RESULTS OF THE INTEGRATED PHASE 1 & 2 PROJECTED PRODUCTION: AFTER-TAX NPV OF US$5.1 BILLION & AVERAGE ANNUAL FREE CASH FLOW OF US$595 MILLION; CONTINUES EVALUATING PHASE 3
Published: 2022-05-26 (Crawled : 14:00) - prnewswire.com
SGML | $14.01 3.47% 3.35% 500K
|
Mining, Quarrying, and Oil and ...
|
| O: 1.17%
H: 13.13%
C: 10.06%
LTUM | $0.0358 33.16% 15K
|
Mining, Quarrying, and Oil and ...
|
| O: 0.88%
H: 3.54%
C: 3.46%
report lithium flow results phase 1 phase 3
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
Published: 2022-05-24 (Crawled : 12:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.04%
H: 1.53%
C: 1.37%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -3.53%
H: 0.0%
C: -1.2%
results phase 3
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.